title: Nifekalant Hydrochloride and Amiodarone Hydrochloride Result in Similar Improvements for 24-Hour Survival in Cardiopulmonary Arrest Patients: The SOS-KANTO 2012 Study.
abstract: BACKGROUND
  Amiodarone (AMD), nifekalant (NIF), and lidocaine (LID) hydrochlorides are widely used for ventricular tachycardia/fibrillation (VT/VF). This study retrospectively investigated the NIF potency and the differential effects of 2 initial AMD doses (≤150 mg or 300 mg) in the Japanese SOS-KANTO 2012 study population.
  
  
  RESULTS
  From 16,164 out-of-hospital cardiac arrest cases, 500 adult patients using a single antiarrhythmic drug for shock-resistant VT/VF were enrolled and categorized into 4 groups (73 LID, 47 NIF, 173 AMD-≤150, and 207 AMD-300). Multivariate analyses evaluated the outcomes of NIF, AMD-≤150, or AMD-300 groups versus LID group. Odds ratios (ORs) for survival to admission were 3.21 [95% confidence interval (CI): 1.38-7.44, P < 0.01] in NIF and 3.09 (95% CI: 1.55-6.16, P < 0.01) in AMD-≤150 groups and significantly higher than those of the LID group. However, the OR was 1.78 (95% CI: 0.90-3.51, P = 0.10) in AMD-300 group and was not significant than LID group. ORs for 24-hour survival were 6.68 in NIF, 4.86 in AMD-≤150, and 2.97 in AMD-300, being significantly higher in these groups.
  
  
  CONCLUSIONS
  NIF and AMD result in similar improvements for 24-hour survival in cardiopulmonary arrest patients, and this suggest the necessity of a randomized control study.
authors: *Tokai University School of Medicine, Kanagawa, Japan; †Nihon University Surugadai Hospital, Tokyo, Japan; ‡Tokyo Bay Urayasu/Ichikawa Medical Center, Chiba, Japan; §Saitama Red Cross Maebashi Hospital, Saitama, Japan; ¶Nihon University School of Medicine, Tokyo, Japan; ‖National Cerebral and Cardiovascular Center Hospital, Osaka, Japan; **National Center of Neurology and Psychiatry, Tokyo, Japan; ††Tokyo Women's Medical University Hospital, Tokyo, Japan; and ‡‡Yokohama City University Medical Center, Kanagawa, Japan.
authors: Mari
authors: M
authors: Amino
authors: Sadaki
authors: S
authors: Inokuchi
authors: Ken
authors: K
authors: Nagao
authors: Yoshihide
authors: Y
authors: Nakagawa
authors: Koichiro
authors: K
authors: Yoshioka
authors: Yuji
authors: Y
authors: Ikari
authors: Hiraku
authors: H
authors: Funakoshi
authors: Katsura
authors: K
authors: Hayakawa
authors: Masakazu
authors: M
authors: Matsuzaki
authors: Atsushi
authors: A
authors: Sakurai
authors: Yoshio
authors: Y
authors: Tahara
authors: Naohiro
authors: N
authors: Yonemoto
authors: Arino
authors: A
authors: Yaguchi
authors: Naoto
authors: N
authors: Morimura
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D058687:Out-of-Hospital Cardiac Arrest / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D011744:Pyrimidinones / Q000627:therapeutic use*; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D011744:Pyrimidinones; C076259:nifekalant; D000638:Amiodarone